Equities Analysts Issue Forecasts for KALV Q2 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Research analysts at HC Wainwright raised their Q2 2026 EPS estimates for KalVista Pharmaceuticals in a report released on Thursday, March 12th. HC Wainwright analyst A. Fein now expects that the specialty pharmaceutical company will post earnings per share of ($0.42) for the quarter, up from their previous forecast of ($0.46). HC Wainwright has a “Buy” rating and a $37.00 price target on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share. HC Wainwright also issued estimates for KalVista Pharmaceuticals’ Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($1.23) EPS, FY2028 earnings at $2.25 EPS, FY2029 earnings at $3.56 EPS and FY2030 earnings at $3.83 EPS.

Several other equities research analysts have also recently issued reports on the stock. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Wall Street Zen upgraded KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Finally, Needham & Company LLC lifted their price target on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $29.40.

KalVista Pharmaceuticals Trading Down 2.5%

NASDAQ KALV opened at $16.94 on Monday. KalVista Pharmaceuticals has a 52 week low of $9.23 and a 52 week high of $19.00. The firm has a 50 day moving average of $15.76 and a two-hundred day moving average of $14.28. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. The stock has a market capitalization of $856.32 million, a PE ratio of -4.29 and a beta of -0.35.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Large investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets grew its holdings in shares of KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $55,000. Wolverine Asset Management LLC purchased a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $57,000. Truvestments Capital LLC boosted its position in shares of KalVista Pharmaceuticals by 253.8% in the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,360 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $63,000.

Insider Activity at KalVista Pharmaceuticals

In other news, CFO Brian Piekos sold 1,767 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $27,512.19. Following the completion of the sale, the chief financial officer owned 13,762 shares in the company, valued at approximately $214,274.34. The trade was a 11.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 6,693 shares of the company’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $16.08, for a total transaction of $107,623.44. Following the completion of the transaction, the chief executive officer owned 451,815 shares of the company’s stock, valued at approximately $7,265,185.20. The trade was a 1.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 33,378 shares of company stock worth $522,290 in the last ninety days. Company insiders own 4.30% of the company’s stock.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.